MX2023005533A - Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina. - Google Patents

Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina.

Info

Publication number
MX2023005533A
MX2023005533A MX2023005533A MX2023005533A MX2023005533A MX 2023005533 A MX2023005533 A MX 2023005533A MX 2023005533 A MX2023005533 A MX 2023005533A MX 2023005533 A MX2023005533 A MX 2023005533A MX 2023005533 A MX2023005533 A MX 2023005533A
Authority
MX
Mexico
Prior art keywords
preparation
method therefor
medicine
application
dione derivative
Prior art date
Application number
MX2023005533A
Other languages
English (en)
Inventor
Hongbo Fei
Feng He
Weikang Tao
Xiaomin Zhang
Weimin Hu
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of MX2023005533A publication Critical patent/MX2023005533A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona un derivado de triazina diona, un método de preparación del mismo y una aplicación del mismo en medicina. Específicamente, se proporciona un derivado de triazina diona representado por la fórmula general (I), un método de preparación para el mismo, una composición farmacéutica que contiene el derivado y un uso del mismo como agente terapéutico, particularmente un uso en la preparación de un inhibidor de miosina y un uso en la preparación de un fármaco para el tratamiento de la miocardiopatía hipertrófica (MCH) o enfermedades del corazón que tienen características fisiopatológicas relacionadas con la MCH.
MX2023005533A 2020-11-20 2021-11-19 Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina. MX2023005533A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202011310827 2020-11-20
CN202110021509 2021-01-08
CN202110244090 2021-03-05
CN202110464375 2021-04-28
PCT/CN2021/131642 WO2022105852A1 (zh) 2020-11-20 2021-11-19 三嗪二酮类衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
MX2023005533A true MX2023005533A (es) 2023-05-25

Family

ID=81708401

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005533A MX2023005533A (es) 2020-11-20 2021-11-19 Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina.

Country Status (10)

Country Link
US (1) US20240010639A1 (es)
EP (1) EP4249474A4 (es)
JP (1) JP2023550444A (es)
KR (1) KR20230110538A (es)
CN (1) CN116323598A (es)
AU (1) AU2021381664A1 (es)
CA (1) CA3198934A1 (es)
MX (1) MX2023005533A (es)
TW (1) TW202227420A (es)
WO (1) WO2022105852A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38358A (es) 2018-08-31 2020-03-31 Cytokinetics Inc Inhibidores de sarcómeros cardíacos
EP4301760A1 (en) 2021-03-04 2024-01-10 Cytokinetics, Inc. Cardiac sarcomere inhibitors
AU2022240693A1 (en) * 2021-03-17 2023-09-07 Hansoh Bio Llc Nitrogen-containing heterocyclic ketones, preparation methods and medicinal uses thereof
TW202411221A (zh) * 2022-05-20 2024-03-16 大陸商江蘇恆瑞醫藥股份有限公司 一種三嗪二酮類衍生物的晶型及製備方法
WO2024056096A1 (zh) * 2022-09-16 2024-03-21 江苏豪森药业集团有限公司 一种含氮杂环酮化合物的晶型及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20160208A1 (es) * 2013-06-21 2016-05-04 Myokardia Inc Compuestos de pirimidinodiona contra estados cardiacos
WO2014205234A1 (en) * 2013-06-21 2014-12-24 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
US9663516B2 (en) * 2014-12-18 2017-05-30 MyoKardia, Inc. Bicyclic-pyrimidinedione compounds
WO2017219948A1 (en) 2016-06-20 2017-12-28 Novartis Ag Crystalline forms of triazolopyrimidine compound
CN117209447A (zh) 2017-07-24 2023-12-12 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
SG10202112960QA (en) 2017-08-04 2021-12-30 Myokardia Inc Mavacamten for use in the treatment of hypertrophic cardiomyopathy
UY38358A (es) * 2018-08-31 2020-03-31 Cytokinetics Inc Inhibidores de sarcómeros cardíacos
EP3873904A1 (en) 2018-10-29 2021-09-08 MyoKardia, Inc. Tetrahydropyran (thp)-substituted bicyclic-pyrimidinedione compounds
CN111116492B (zh) * 2019-01-25 2021-07-09 青岛吉澳医药科技有限公司 氘代苯甲氨嘧啶二酮衍生物及其用途
CN110698415B (zh) 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
EP4249474A1 (en) 2023-09-27
WO2022105852A1 (zh) 2022-05-27
KR20230110538A (ko) 2023-07-24
EP4249474A4 (en) 2024-04-17
TW202227420A (zh) 2022-07-16
US20240010639A1 (en) 2024-01-11
CN116323598A (zh) 2023-06-23
AU2021381664A1 (en) 2023-06-15
JP2023550444A (ja) 2023-12-01
CA3198934A1 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
MX2023005533A (es) Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina.
UA86977C2 (ru) Производные гидантоина для лечения обструктивных болезней дыхательных путей
SG160364A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
MX2023007853A (es) Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo.
BRPI0512075A (pt) composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença
TW200833663A (en) Therapeutic agents
ATE557015T1 (de) 3,4-diarylpyrazole als proteinkinaseinhibitoren
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
BRPI0517426A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito anti-proliferação celular, para produzir um efeito inibitório de cdk2, e para tratar uma doença em um animal de sangue quente
BRPI0606930A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, métodos para a produção de um efeito de inibição de b-raf em um animal de sangue quente, para a produção de um efeito anti-cáncer em um animal de sangue quente e para o tratamento de doenças de um animal em um animal de sangue quente
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
WO2009063202A3 (en) Use of crth2 antagonist compounds
MXPA05007857A (es) Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
TW200635878A (en) Hydroxybiphenylcarboxylic acids and derivatives, processes for preparing them and their use
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
PH12021551232A1 (en) Haloallylamine compounds and application thereof
RU2013148817A (ru) Комбинации соединений-ингибиторов акт и мек и способы их применения
AR043259A1 (es) Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello
MX2023003627A (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer.
MX2022015554A (es) Moduladores de molecula peque?a de interleucina 17 (il-17).
MX2023011166A (es) Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina.
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer